Battle-scarred Pan Pacific Aggregates (PPA) says it should start granite production before January after raising £1.1 million at a discounted 0.5p.
Based in British Columbia and quoted on AIM, PPA, which is emerging from a series of setbacks and upheavals, is now in a position to move its Pumptown granite quarry into production this quarter, declares managing director William Voaden. KC Investments, a vehicle for City dealer Keith Catchpole, has taken nearly a fifth of the placing and VSA Capital, an investment firm headed by Voaden, has been granted warrants to subscribe for 0.7 per cent of the enlarged capital at 0.5p over three years.
Floated in 2005 at 88p, PPA shares collapsed all the way to 0.25p after its original project ran into local opposition and then Pumptown was bedevilled with logistical and infrastructure problems and the company fell out with its local partners. These hurdles have mostly now been overcome and PPA directors talk of target production of one million tonnes a year from Pumptown, with hoped-for gross margins of 2.65p a tonne and a chance to supply regional infrastructure projects, some related to the 2010 Vancouver Winter Olympics.
The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info
Latest small-cap and growth company news
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
There are many smaller company funds out there; but the new management of Gresham House Strategic (AIM: GHS) is trying to stand out from the crowd by bringing a ‘private equity’ approach to the public market arena. For investors who supplement their own ‘DIY’ stock picking with selected funds, GHS could be an interesting option.
Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.
Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.
Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition.
Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.
The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...